Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS)

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1653-1659

  Viladés, Consuelo ^a   Escoté, Xavier ^a,b   López Dupla, Miguel ^a   Martinez, Esteban ^c   Domingo, Pere ^d   Asensi, Víctor ^e   Leal, Manuel ^f   Peraire, Joaquim ^a   Inza, Maria Isabel ^a   Arnedo, Mireia ^c   Gutiérrez, Mar ^d   Valle Garay, Eulalia ^e   Ferrando Martinez, Sara ^f,g   Olona, Montserrat ^a   Alba, Verónica ^a   Sirvent, Joan Josep ^a   Gatell, Josep M ^c   Vidal, Francesc ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF OVIEDO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Genetics; Inflammation; Microbial translocation

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN MD 2; PROTEINASE INHIBITOR; STAVUDINE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; ZIDOVUDINE; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ADULT; AGE; ARTICLE; BACTERIAL TRANSLOCATION; BLOOD LEVEL; CD14 GENE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; LBP GENE; MAJOR CLINICAL STUDY; MALE; MD2 GENE; MULTICENTER STUDY (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TLR4 GENE; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; GENETICS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SIGNAL TRANSDUCTION; VIROLOGY;

ACUTE-PHASE PROTEINS; ADULT; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARRIER PROTEINS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RISK FACTORS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; VIRAL LOAD;

EID: 84903880134     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku032     Document Type: Article

References (36)

1. Guaraldi G, Stentarelli C, Zona S et al. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 2013; 73: 1431-50.
2. Johnson JA, Albu JB, Engelson ES et al. Increased systemic and adipose tissue cytokines in patients with HIV-1-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: E261-71.
3. Tsiodras S, Perelas A, Wanke C et al. The HIV-1/HAART associated metabolic syndrome-novel adipokines, molecular associations and therapeutic implications. J Infect 2010; 61: 101-13.
4. Samaras K, Gan SK, Peake PW et al. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV-1 infection. Obesity 2009; 17: 53-9.
5. Koethe JR, Dee K, Bian A et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and non-obese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retrov 2013; 29: 1019-25.
6. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV-1-infected patients: lessons for obesity research. Int J Obes 2007; 31: 1763-76.
7. Gonzalez-Quintela A, Alonso M, Campos J et al. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 2013; 8: e54600.
8. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol 2013; 216: T1-T15.
9. Moreno-Navarrete JM, Ortega F, Serino M et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes 2011; 36: 1442-9.
10. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 2007; 4: 42-7.
11. Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E et al. Long-term suppressive combined antiretroviral therapy treatment does not normalize sCD14 levels. J Infect Dis 2013; 297: 1221-5.
12. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
13. Cassol E, Malfeld S, Mahasha P et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202: 723-33.
14. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-51.
15. Hendel H, Winkler C, An P et al. Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism. J Acquir Immune Defic Syndr 2001; 15: 507-11.
16. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
17. Escoté X, Miranda M, Veloso S et al. Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. J Acquir Immune Defic Syndr 2011; 57: 16-23.
18. Ceperuelo-Mallafré V, Escoté X, Viladés C et al. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. HIV Med 2012; 13: 297-303.
19. Chien JW, Boeckh MJ, Hansen JA et al. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008; 111: 2462-9.
20. Hubacek JA, Rothe G, Pit'ha J et al. C(2260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99: 3218-20.
21. Cuda C, Badawi A, Karmali M et al. Polymorphisms in Toll-like receptor 4 are associated with factors of the metabolic syndrome and modify the association between dietary saturated fat and fasting high-density lipoprotein cholesterol. Metabolism 2011; 60: 1131-5.
22. Kolz M, Baumert J, Müller M et al. Association between variations in the TLR4 gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet 2008; 9: 9.
23. Enquobahrie DA, Smith NL, Bis JC et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol 2008; 101: 1683-8.
24. Zeng L, Zhang AQ, Gu W et al. Identification of haplotype tag SNPs within the whole myeloid differentiation 2 gene and their clinical relevance in patients with major trauma. Shock 2012; 37: 366-72.
25. Romero-Sánchez M, González-Serna A, Pacheco Y et al. Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 2012; 65: 431-8.
26. Vidal F, Domingo P, Viladés C et al. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opin Drug Metab Toxicol 2011; 7: 1365-82.
27. Moreno-Navarrete JM, Escoté X, Ortega F et al. A role for adipocyte-derived lipopolysaccaride-binding protein in inflammationand obesity-associated adipose tissue dysfunction. Diabetologia 2013; 56: 2524-37.
28. Ioannidis JP, Ntzani EE, Trikalinos TA et al. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-9.
29. Asensi V, Rego C, Montes H et al. IL-1b (+3945C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral therapy (HAART) against lipodystrophy syndrome. Genet Med 2008; 10: 215-23.
30. Vasallo M, Mercié P, Cottalorda J et al. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J 2012; 9: 174.
31. Ancuta P, Kamat A, Kunstman KJ et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3: e2516.
32. Marks MA, Rabkin CS, Engels EA et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2013; 27: 469-74.
33. Langkilde A, Petersen J, Klausen HH et al. Inflammation in HIV-infected patients: impact of HIV lifestyle, body composition, and demography-a cross sectional cohort study. PLoS One 2012; 7: e51698.
34. Koethe JR, Bian A, Shintani AK et al. An association between adiposity and serum levels of macrophage inflammatory protein-1a and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Antivir Ther 2013; 18: 729-33.
35. Guaraldi G, Luzi K, Bellistri GM et al. CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients. J Acquir Immune Defic Syndr 2013; 64: 360-6.
36. Koethe JR, Hulgan T, Niswender K. Adipose tissue and immune function: a review of evidence relevant to HIV infection. J Infect Dis 2013; 208: 1194-201.